Eli Lilly's Mounjaro Q1 Sales Top $8bn As Type-2 Diabetes Approval Broadens In Global Markets

Eli Lilly reported first-quarter net product sales of Mounjaro, the company's flagship GLP-1 receptor-agonist franchise, at $8.1 billion — approximately 65% ahead of the equivalent year-ago quarter and ahead of analyst consensus, confirming the substantial continuing demand momentum across the global Type-2 diabetes and obesity-treatment categories that the molecule has been progressively addressing.

The headline lift was driven by a combination of continued strong US prescription-volume growth, the substantial international-market expansion that the molecule has been progressing through since the original 2022 launch, and the meaningful pricing-and-mix uplift that has accompanied the broadening therapeutic-indication framework across the regulatory cycle. The international-market revenue component grew approximately 130% year-on-year, with the European, Japanese, and selected emerging-market launches all contributing materially to the consolidated franchise growth.

The supply-side dynamic — which has been the principal constraint on the franchise's commercial trajectory since the original launch — has continued to ease through the quarter. The substantial capacity investments Eli Lilly has been progressing across its Indianapolis manufacturing base, the recently-acquired Catalent fill-finish capacity, and the new contract-manufacturing partnerships have all collectively brought the company's effective production capacity closer to the underlying customer-demand profile. Wholesaler-level inventory data through Q1 indicates the substantial supply shortages that defined 2023-24 have now largely resolved.

The competitive dynamic against Novo Nordisk's parallel Wegovy and Ozempic franchises continues to evolve. The two companies' combined GLP-1 receptor-agonist revenue across Q1 reached approximately $19 billion on a global basis — an extraordinary scaling for a single therapeutic category — and the underlying market growth trajectory continues to support the bull-case modelling that several sell-side analyst groups have been pencilling in for the wider category through the rest of the decade.

For investors holding the wider pharmaceutical-sector complex, the Eli Lilly Q1 print is the cleanest single confirmation that the GLP-1 receptor-agonist cycle is genuinely durable rather than the more transient consumer-demand-driven phenomenon some early-cycle commentary had framed it as. The principal forward variable across the rest of the calendar year is the continued progression of the pipeline-stage molecules — particularly the CagriSema Phase Three readout expected from Novo Nordisk in the second half of the year — which will substantially shape the wider competitive landscape through the late-decade commercial cycle.